ID93 + GLA-3M-052-LS: TB Vaccine Candidate Immunogenicity and Efficacy Data

Emily Voigt published data on May 1, 2026, assessing a next-generation tuberculosis vaccine candidate. The dataset likely contains immunogenicity and protective efficacy results from a mouse model study using the Collaborative Cross 004 strain. The research evaluated the ID93 antigen combined with the GLA-3M-052-LS adjuvant system administered via heterologous routes.

Use Cases

• Compare immunostimulatory profiles of different vaccine candidates based on the described desirability index.
• Analyze mucosal immune responses, such as lung antibody and Th1 CD4+ T cell levels, induced by heterologous intramuscular-intranasal regimens.
• Evaluate the protective efficacy of BCG-primed vaccine boosts by comparing Mtb burden in lungs post-challenge.
• Study the role of synthetic TLR4 and TLR7/8 ligands in liposomal adjuvant systems for TB vaccine development.

Strengths

• Data is associated with a specific, peer-reviewed research methodology using the Collaborative Cross 004 mouse strain.
• The dataset is licensed under CC-BY-4.0, permitting broad reuse with attribution.
• The description provides a clear scientific narrative linking adjuvant, route of administration, and immunological outcomes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale analyses.
• The 3.2 MB file size suggests a relatively small dataset, potentially limiting statistical power for some analyses.

Provenance

Source

Emily Voigt via figshare.

Collection Method

Data generated from immunogenicity and challenge experiments in a mouse model, as described in the accompanying document.

Freshness

Last updated 2026-05-01 05:24:45; freshness should be verified.